YOLFTbeta
Stevanato Group SpA

Stevanato Group SpA

STVN · NYSE · Healthcare / Medical Instruments & Supplies

15.80USD+1.44 (+10.03%)

Price History

Full chart

Market Stats

Previous Close14.36
Open14.67
Day Range14.40 – 16.05
52-Week Range12.05 – 23.92
Volume1.46M
Market Cap3.92B
P/E (TTM)24.34
Forward P/E21.74
EPS0.59
Dividend Yield0.43%
Beta0.80
50-Day Avg19.25
200-Day Avg17.92

About

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Franco Stevanato
  • Employees6.01K
  • HeadquartersVia Molinella 17, Piombino Dese, PD, Italy, 35017, USA
  • Websitehttps://www.stevanatogroup.com

Leadership

  • Mr. Franco StevanatoCEO & Executive Chairman · b. 1973
  • Mr. Marco Dal LagoChief Financial Officer · b. 1973
  • Ms. Lisa MilesChief Communications & Investor Relations Officer
  • Ms. Carla CostaChief Human Resources Officer
  • Mr. Mauro StocchiChief Business Strategy Officer · b. 1966
  • Mr. Michele MonicoPresident of DDS & IVD Business Unit
  • Mr. Alberto CagnatoSenior Vice President of DCS Operations
  • Mr. Riccardo MarconSenior Vice President of Sales & Marketing of DCS
  • Ms. Veda K. Walcott CLS (NCA), MBA, MT (ASCP)Chief Quality & Regulatory Officer
  • Mr. Alessandro MelchiorrePresident of Engineering Business Unit

Financials

Income Statement

Currency: EUR2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue536.54M662.04M843.92M983.68M1.09B1.10B1.14B
Growth (%)-+23.39%+27.47%+16.56%+10.34%+1.72%+3.21%
Cost of Revenue398.52M467.86M578.51M663.88M745.46M801.72M809.15M
Gross Profit138.02M194.18M265.40M319.80M339.89M302.32M330.33M
Gross Margin25.72%29.33%31.45%32.51%31.32%27.38%28.99%
Operating Expense75.80M91.07M103.18M127.37M139.17M141.18M147.25M
Operating Income62.22M103.11M162.22M192.43M200.72M161.14M183.08M
Operating Margin11.60%15.57%19.22%19.56%18.49%14.60%16.07%
EBITDA106.54M156.38M226.93M256.40M272.35M247.80M292.01M
EBITDA Margin19.86%23.62%26.89%26.07%25.09%22.45%25.63%
Net Income39.20M78.51M134.32M142.85M145.63M117.78M134.28M
Net Income Margin7.31%11.86%15.92%14.52%13.42%10.67%11.78%
R&D7.83M17.39M29.62M34.39M35.67M31.67M24.40M
R&D as % of Total Revenue1.46%2.63%3.51%3.50%3.29%2.87%2.14%
Interest Expense5.30M6.79M4.87M3.94M4.32M6.86M21.80M
Interest Expense % of Total Revenue0.99%1.03%0.58%0.40%0.40%0.62%1.91%

Balance Sheet

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets781.58M882.18M967.98M1.42B1.66B2.07B2.33B2.54B
Total Liabilities550.18M616.74M657.84M577.18M663.79M938.93M924.43M1.06B
Total Equity231.56M265.49M310.50M842.07M996.13M1.13B1.40B1.49B
Cash74.52M85.39M115.60M411.04M228.74M69.60M98.27M130.54M
Total Debt317.07M375.67M363.01M244.29M218.37M396.59M428.97M470.70M
Net Debt242.56M290.28M247.41M-166.75M-10.37M326.99M330.70M340.16M

Cash Flow

Currency: EUR2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow42.57M155.66M133.30M103.30M105.21M155.78M274.79M
Investing Cash Flow-74.34M-96.09M-96.43M-242.95M-421.22M-310.21M-262.15M
Financing Cash Flow42.17M-26.52M254.80M-44.50M158.03M183.22M21.19M
Capital Expenditure73.91M96.00M113.18M243.13M441.93M313.57M253.35M
Free Cash Flow-31.33M59.65M20.12M-139.83M-336.72M-157.79M21.44M
Dividends Paid6.17M8.90M11.20M13.50M14.29M14.46M14.16M
FCF to OCF-73.60%38.32%15.09%-135.36%-320.04%-101.30%7.80%
Dividend Paid to FCF-19.69%14.92%55.67%-9.65%-4.25%-9.16%66.02%

Earnings

Report DateMar 31, 2020Mar 31, 2021Jun 2, 2021Aug 19, 2021Nov 9, 2021Mar 8, 2022May 10, 2022Aug 4, 2022Nov 8, 2022Mar 2, 2023May 4, 2023Jul 28, 2023Oct 31, 2023Mar 7, 2024May 9, 2024Aug 6, 2024Nov 5, 2024Mar 6, 2025May 8, 2025Aug 5, 2025Nov 6, 2025Mar 5, 2026May 7, 2026Aug 4, 2026Nov 3, 2026Nov 5, 2026
EPS Estimate0.000.00-0.150.110.100.110.120.130.160.130.140.160.190.120.110.140.180.100.120.150.170.120.150.170.18
EPS Actual0.030.180.410.140.120.130.120.120.150.180.120.150.160.180.090.100.130.190.110.130.160.210.130.160.18-
Surprise----6.67%9.09%30.00%9.09%0.00%15.38%12.50%-7.69%7.14%0.00%-5.26%-25.00%-9.09%-7.14%5.56%10.00%8.33%6.67%23.86%8.33%6.67%5.88%-
Timing---Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap3.92B
Enterprise Value4.19B
Trailing P/E24.34
Forward P/E21.74
PEG Ratio1.73
Price / Sales3.14
Price / Book2.12
EPS0.59
Book Value6.56
Revenue (TTM)1.25B
Gross Profit (TTM)366.67M
EBITDA308.33M
Profit Margin11.25%
Operating Margin17.95%
Return on Equity9.26%
Return on Assets5.51%
Shares Outstanding49.83M
Shares Float49.02M
Beta0.80
Dividend Yield0.43%
Dividend Rate0.06
Payout Ratio9.14%

Analyst Ratings

Buy
Based on 13 analystsTarget 19.46
  • Strong Buy
    6
  • Buy
    3
  • Hold
    4

Ownership Breakdown

Institutions
101.08%
Insiders
1.83%
Retail / Other
0.00%

Top Institutional Holders

  • Conestoga Capital Advisors, LLC
    7.01M2.57%
  • Neuberger Berman Group LLC
    5.62M2.06%
  • TimesSquare Capital Management, LLC
    3.25M1.19%
  • Van Berkom and Associates Inc
    2.86M1.05%
  • Artisan Partners Limited Partnership
    2.60M0.95%
  • BAMCO Inc
    2.49M0.91%
  • Morgan Stanley - Brokerage Accounts
    1.31M0.48%
  • Crédit Agricole S.A.
    1.30M0.48%
  • Wellington Management Company LLP
    1.25M0.46%
  • Arnhold & S. Bleichroeder Advisers, LLC
    1.22M0.45%
  • Ranger Investment Management LP
    1.19M0.43%
  • Royce & Associates, LP
    916.36K0.34%
  • Deutsche Bank AG
    834.22K0.31%
  • New York State Common Retirement Fund
    791.84K0.29%

Top Fund Holders

  • Neuberger Genesis Inv
    3.04M1.11%
  • Conestoga Small Cap Investors
    2.38M0.87%
  • Baron Discovery Institutional
    1.68M0.62%
  • DPAM B Eqs NewGems Sust A EUR Dis
    1.30M0.48%
  • American Century Small Cap Growth Inv
    977.76K0.36%
  • Artisan Small Cap Investor
    813.15K0.30%

Dividends

20261×
0.06Jun 11, 2026
20251×
0.06Jun 5, 2025
20241×
0.06Jun 4, 2024
20231×
0.06Jun 7, 2023
20221×
0.05Jun 13, 2022